By specifically targeting VPS34, it disrupts autophagy and impedes the trafficking of late endosomes to lysosomes, demonstrating preclinical efficacy in tumor types that rely heavily on autophagic processes [73]. The gene discussed is PIK3C3; the disease is neoplasm.